NEW YORK (GenomeWeb) – Avant Diagnostics and Amarantus Diagnostics this week signed a letter of intent to acquire clinical proteomics firm Theranostics Health as part of the two firms' planned merger.

The deal, which is expected to close by the end of March, brings together three companies that have to date struggled to ramp their molecular testing businesses in hopes that the combined outfit will be better positioned to succeed in the market, suggested Gerald Commissiong, president and CEO of Amarantus Bioscience, the parent firm of Amarantus Diagnostics.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Human Longevity alleges that Craig Venter stole trade secrets in a lawsuit filed against the J. Craig Venter Institute.

A new analysis critiques the analysis and conclusions of the Atacama mummy genome sequencing study.

In PLOS this week: transcription levels linked to uracil mutations, transcriptomic analysis of medicinal leech, and more.

An Associated Press poll finds that most US adults say they'd want to know whether they carried a gene variant predisposing them to an incurable disease.

Aug
23
Sponsored by
Tecan

This webinar will discuss an automated, high-throughput method of generating high-quality antigens and antibodies.